Stock Events

Protokinetix 

$0.01
6
-$0-3.69% Wednesday 19:48

Statistics

Day High
0.01
Day Low
0.01
52W High
0.03
52W Low
0.01
Volume
141,520
Avg. Volume
59,426
Mkt Cap
5.15M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

31OctExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0
-0
-0
-0
Expected EPS
N/A
Actual EPS
-0.0013

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PKTX. It's not an investment recommendation.
Alphabet
78395
GOOGL
Apple
68177
AAPL
Microsoft
63621
MSFT
Amazon
59331
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap130.59B
Regeneron Pharmaceuticals, Inc. competes in the biotechnology field focusing on developing treatments for eye diseases, inflammatory conditions, and cancer, similar to Protokinetix's focus on therapeutic applications.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.99B
Vertex Pharmaceuticals Incorporated is involved in creating therapies for treating cystic fibrosis and other serious diseases, competing in the biotech sector with innovative treatments.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops and markets medicines in areas of unmet medical need, overlapping with Protokinetix's mission.
AMGEN
AMGN
Mkt Cap179.38B
Amgen Inc. is a biotechnology pioneer that discovers, develops, manufactures, and delivers innovative human therapeutics, similar to Protokinetix's work in biotech.
Biogen
BIIB
Mkt Cap29.83B
Biogen Inc. focuses on developing therapies for neurological diseases, competing with Protokinetix in the broader biotech and therapeutic research industry.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics AG is a gene editing company that develops transformative gene-based medicines for serious diseases, presenting a competitive edge in innovative treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap33.72B
Alnylam Pharmaceuticals, Inc. is engaged in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics, a novel approach that could compete with Protokinetix's therapeutic strategies.
Novo Nordisk
NVO
Mkt Cap620.4B
Novo Nordisk A/S is a global healthcare company with more than 95 years of innovation and leadership in diabetes care, also expanding into biopharmaceuticals, potentially competing with Protokinetix.
Biomarin Pharmaceutical
BMRN
Mkt Cap17.36B
BioMarin Pharmaceutical Inc. specializes in enzyme replacement therapies and other novel treatments for rare genetic diseases, competing in the innovative treatment space similar to Protokinetix.

About

Biotechnology
Health Technology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.
Show more...
CEO
Country
US
ISIN
US7437221002

Listings

US
PKTX